A Clinical Study in Health Subjects to Evaluate 9MW1411 Injection

Summary

This is a Phase 1, first time in human study enrolling approximately 42 healthy adult subjects (18-45 yrs) from one study site. The purpose of this study is to evaluate the safety, tolerability and PK of MW14 in healthy adult volunteers administered as a single IV dose compared with placebo, across 5 cohorts. The 5 dose cohorts will enroll sequentially. Subjects will be followed for safety from the time of Informed Consent through 85 days post dose.

Timeline

Start

2021-04-16

Primary completion

2021-08-17

Completion

2021-08-17

Drugs

Indications